Anti-obesity agent comprising high-purity epa
AssigneeMochida Pharmaceutical Co., Ltd.
InventorsTakayuki Ishida, Hiroyuki Kawano
Life of this patent
Estimating the term…
Abstract
The present invention provides an agent for preventing the increase in a body weight (or for decreasing a body weight) or an anti-obesity agent each comprising at least one component selected from the group consisting of EPA and pharmaceutically acceptable salts, esters and derivatives thereof as an active ingredient for obesity in which the increase in the formation of hepatic lipid or the occurrence of fatty liver is mild, preferably the increase in the formation of hepatic lipid or the occurrence of fatty liver is not observed.
Claims19
-8. (canceled)
A method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity comprising the step of administering an agent for suppressing body weight gain (for reducing body weight) or an anti-obesity agent containing at least one member selected from EPA and pharmaceutically acceptable salts, esters, and derivatives thereof as its effective component to a patient suffering from obesity, and in particular, obesity of a type wherein enhancement of hepatic lipogenesis or fatty liver is mild or preferably not recognized.
A method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity, comprising the step of administering an agent for suppressing body weight gain (for reducing body weight) or an anti-obesity agent containing at least one member selected from EPA and pharmaceutically acceptable salts, esters, and derivatives thereof as its effective component, for combined administration with at least one compound selected from CETP inhibitors which is a second effective component.
Dependencies are inferred from the claim text.